From The Editor
-
Why One Biopharma Simultaneously Built Two CAR T Manufacturing Facilities On Two Separate Continents During A Pandemic
2/11/2022
Cellectis SVP of U.S. Manufacturing and Site Head Steve Doares joined the company as it kicked off simultaneous construction of manufacturing plants in Raleigh and Paris—and just as the pandemic began wreaking havoc on biopharmaceutical supply chains. He lived to tell us about it.
-
Vaccine Manufacturing: Chasing COVID’s Long Tail
1/31/2022
A host of biopharma companies continue to pour resources into coronavirus vaccine candidates. Among them, iBio stands out with a unique target region (hint: it’s not a spike protein) and an even more unique manufacturing paradigm (hint: it’s not mRNA).
-
Genomic Testing + Proven mAb = Precision Oncology Medicine
1/31/2022
Precision medicine startup Elevation Oncology is leveraging RNA-based next-generation sequencing to put a proven monoclonal antibody to work in cancer patients with a specific genetic alteration.
-
Reengineering Biologics Manufacturing And Access With Spirulina
1/24/2022
The “democratization” of biologics requires cost, time, and resource elimination from cell culture to administration and every step in between. Here’s how one innovative emerging biotech is leveraging one of the world’s oldest and most prolific organisms to that end.
-
Mastery Of The mAb
1/14/2022
Akesobio’s unrelenting focus on building a deep pipeline of clinical-stage antibodies has resulted in a pipeline of twelve candidates addressing thirty-seven indications, some twenty-five concurrent clinical trials, and a host of pre-IND programs. It got there in just ten years.
-
Inside Homology Medicines’ Decision To Build
1/12/2022
Burned by CMO supply and capacity issues in the past, Homology President & CEO Artur Tzianabos, Ph.D. says the company’s investment in GMP manufacturing facilities will pay dividends in timeline control and regulatory efficiency.
-
The Next Pandemic: Biopharma’s Opportunities & Obligations
1/5/2022
What role will you and your company play in the next public health emergency, and why should you be concerned about it now? Learn from three biopharma leaders as they share insight into the plans they’re making to step up for global human health when the need arises.
-
Beyond Parenteral: Alternative Administration Of Biologics Shows Promise
12/21/2021
2022 could be a breakout year for oral, intranasal, and inhalable biologics. As innovative biopharma companies clear formulation, stability, and efficacy hurdles, market forecasts are rising fast.
-
The “Digitization” Of Therapeutics
12/17/2021
Precision Nanosystems founder James Taylor, Ph.D. believes genomic medicine will soon dominate, and he says genomic medicine design tools are coming to a laboratory benchtop near you.
-
Flexible Manufacturing & Single Use: A Story Of Love And Hate
12/6/2021
Flexible biopharma manufacturing facilities and the single-use tech that supports them are in vogue, fueled by a groundswell of clinical-stage advanced therapies and the need for speed to advance them. Sarepta’s Brian Winstead shares the ups and downs of the approach at Sarepta Therapeutics.